Lee2016 - Blood Coagulation Model

  public model
Model Identifier
Short description
Blood coagulation model derived from Nayak2015.
Related Publication
  • A quantitative systems pharmacology model of blood coagulation network describes in vivo biomarker changes in non-bleeding subjects.
  • Lee D, Nayak S, Martin SW, Heatherington AC, Vicini P, Hua F
  • Journal of thrombosis and haemostasis : JTH , 12/ 2016 , Volume 14 , Issue 12 , pages: 2430-2445 , PubMed ID: 27666750
  • PharmaTherapeutics Clinical Research, Pfizer Inc., Cambridge, MA, USA.
  • Essentials Baseline coagulation activity can be detected in non-bleeding state by in vivo biomarker levels. A detailed mathematical model of coagulation was developed to describe the non-bleeding state. Optimized model described in vivo biomarkers with recombinant activated factor VII treatment. Sensitivity analysis predicted prothrombin fragment 1 + 2 and D-dimer are regulated differently.Background Prothrombin fragment 1 + 2 (F1 + 2 ), thrombin-antithrombin III complex (TAT) and D-dimer can be detected in plasma from non-bleeding hemostatically normal subjects or hemophilic patients. They are often used as safety or pharmacodynamic biomarkers for hemostatis-modulating therapies in the clinic, and provide insights into in vivo coagulation activity. Objectives To develop a quantitative systems pharmacology (QSP) model of the blood coagulation network to describe in vivo biomarkers, including F1 + 2 , TAT, and D-dimer, under non-bleeding conditions. Methods The QSP model included intrinsic and extrinsic coagulation pathways, platelet activation state-dependent kinetics, and a two-compartment pharmacokinetics model for recombinant activated factor VII (rFVIIa). Literature data on F1 + 2 and D-dimer at baseline and changes with rFVIIa treatment were used for parameter optimization. Multiparametric sensitivity analysis (MPSA) was used to understand key proteins that regulate F1 + 2 , TAT and D-dimer levels. Results The model was able to describe tissue factor (TF)-dependent baseline levels of F1 + 2 , TAT and D-dimer in a non-bleeding state, and their increases in hemostatically normal subjects and hemophilic patients treated with different doses of rFVIIa. The amount of TF required is predicted to be very low in a non-bleeding state. The model also predicts that these biomarker levels will be similar in hemostatically normal subjects and hemophilic patients. MPSA revealed that F1 + 2 and TAT levels are highly correlated, and that D-dimer is more sensitive to the perturbation of coagulation protein concentrations. Conclusions A QSP model for non-bleeding baseline coagulation activity was established with data from clinically relevant in vivo biomarkers at baseline and changes in response to rFVIIa treatment. This model will provide future mechanistic insights into this system.
Submitter of the first revision: Matthew Roberts
Submitter of this revision: Matthew Roberts
Modellers: Matthew Roberts

Metadata information

isDescribedBy (1 statement)
PubMed 27666750

isVersionOf (1 statement)
Gene Ontology blood coagulation

Curation status


Connected external resources

SBGN view in Newt Editor

Name Description Size Actions

Model files

Lee2016.xml SBML L2V4 representation of Lee2016 - Blood Coagulation Model 295.70 KB Preview | Download

Additional files

Lee2016.cps Model COPASI file. Attempt at curating and reproducing red curves of figure 2 D. 486.03 KB Preview | Download

  • Model originally submitted by : Matthew Roberts
  • Submitted: Jun 6, 2018 1:50:19 PM
  • Last Modified: Jun 6, 2018 1:50:19 PM
  • Version: 2 public model Download this version
    • Submitted on: Jun 6, 2018 1:50:19 PM
    • Submitted by: Matthew Roberts
    • With comment: Edited model metadata online.